Call Start: 16:30 January 1, 0000 5:23 PM ET Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2022 Earnings Conference Call November 14, 2022 16:30 ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Matteo Levisetti - Senior Vice President of Clinical Development Kerri Millar - Chief Financial Officer Conference Call Participants Reni Benjamin - JMP Securities Stephen Willey - Stifel Mark Breidenbach - Oppenheimer Ted ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38327 Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3324577 (State or other jurisd ...

Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2022 Earnings Conference Call August 23, 2022 4:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Matteo Levisetti - SVP, Clinical Development Kerri Millar - Chief Financial Officer Conference Call Participants Stephen Willey - Stifel Reni Benjamin - JMP Securities Mark Breidenbach - Oppenheimer Operator Greetings and welcome to the Cue Biopharma Update Call. At t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38327 Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3324577 (State or other jurisdictio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38327 Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3324577 (State or other jurisdicti ...

02139 (ZipCode) | --- | --- | --- | |------------------------------------------|------------------------------------------------------------------|-------------------------------------------------------------| | Title of each class | registered pursuant to Section 12(b) \nTrading Symbol(s) | of the Act: \nName of each exchange on which registered | | Common Stock, par value $0.001 per share | CUE | Nasdaq Capital Market | UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38327 Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3324577 (State or other jurisd ...

Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2021 Results Conference Call August 17, 2021 4:30 PM ET Company Participants Dr. George Zavoico - VP, IR & Corporate Development Dan Passeri - Chief Executive Officer Dr. Anish Suri - President & Chief Scientific Officer Dr. Ken Pienta - Acting Chief Medical Officer Dr. Matteo Levisetti - SVP, Clinical Development Kerri-Ann Millar - Chief Financial Officer Conference Call Participants Mark Breidenbach - Oppenheimer Stephen Wiley - Stifel Tom Shrader - BTIG Brian Skorney - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CUE Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCH ...

Cue Biopharma, Inc. (NASDAQ:CUE) Q1 2021 Earnings Conference Call May 17, 2021 4:30 PM ET Company Participants George Zavoico - VP, IR & Corporate Development Daniel Passeri - CEO & Director Anish Suri - President & Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Matteo Levisetti - SVP, Clinical Development Kerri-Ann Millar - VP, Finance, Principal Finance & Accounting Officer Conference Call Participants Tom Shrader - BTIG Mark Breidenbach - Oppenheimer Reni Benjamin - JMP Securities Ste ...